Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1Phase 1 1

Status

Active not recruiting 4

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Lymphoma, Large B-Cell, Diffuse 23Burkitt Lymphoma 14Sarcoma 13Neoplasms 11Lymphoma, Follicular 11Lymphoma 10Hodgkin Disease 9Breast Neoplasms 9Triple Negative Breast Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Endometrial Neoplasms 8Ovarian Neoplasms 7Lymphoma, B-Cell 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Wilms Tumor 4Recurrence 4Osteosarcoma 4Neoplasm Metastasis 4Liposarcoma 4Fallopian Tube Neoplasms 4Sarcoma, Ewing 3Neuroblastoma 3Lymphoproliferative Disorders 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3Leiomyosarcoma 3

Interventions

Paclitaxel 22Bevacizumab 20Carboplatin 19liposomal doxorubicin 14Specimen Handling 14Magnetic Resonance Spectroscopy 13olaparib 12Topotecan 9Gemcitabine 9Biopsy 8pembrolizumab 7Taxes 6Immunoglobulin G 6Disulfides 6niraparib 4mirvetuximab soravtansine 4cediranib 4Doxorubicin 4oregovomab 3Nivolumab 3Cyclophosphamide 3sarilumab 2rucaparib 2cemiplimab 2berzosertib 2adavosertib 2Oxaliplatin 2Docetaxel 2Cisplatin 2Biosimilar Pharmaceuticals 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Doxorubicin × 90 days × Clear all
NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
579 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02839707 2026-06-01

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
444 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04092270 2026-05-13

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡